Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Cortes

Showing results (341-350 of 584) with videos related to

Pageof 59
Sort By:
Cancer|March 26, 2004
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemiaFrancis J Giles, Martin S Tallman, Guillermo Garcia-Manero, et al.
Blood|August 6, 2015
Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitorsWei Wang, Jorge E Cortes, Pei Lin, et al.
American Journal of Hematology|August 18, 2016
Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinibJorge E Cortes, Hanna J Khoury, Hagop M Kantarjian, et al.
Leukemia Research|June 15, 2007
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasiaFrancis J Giles, Alan F List, Michael Carroll, et al.
Blood|October 24, 2002
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responsesHagop M Kantarjian, Jorge E Cortes, Susan O'Brien, et al.
Leukemia & Lymphoma|June 23, 2025
Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITYMichael J Mauro, Rüdiger Hehlmann, Loretta A Williams, et al.
Leukemia|February 5, 2014
Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategyC D DiNardo, N Daver, N Jain, et al.
Patient Education and Counseling|March 22, 2021
Utility of a virtual counselor (VICKY) to collect family health histories among vulnerable patient populations: A randomized controlled trialCatharine Wang, Michael K Paasche-Orlow, Deborah J Bowen, et al.
British Journal of Haematology|October 3, 2002
Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survivalFrancis J Giles, Hagop M Kantarjian, B Nebiyou Bekele, et al.
Blood|June 8, 2018
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in <i>FLT3</i>-ITD-mutated, relapsed or refractory AMLJorge E Cortes, Martin S Tallman, Gary J Schiller, et al.
Pageof 59

Showing results (341-350 of 584) with videos related to

Sort By:
Pageof 59
Cancer|March 26, 2004
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemiaFrancis J Giles, Martin S Tallman, Guillermo Garcia-Manero, et al.
Blood|August 6, 2015
Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitorsWei Wang, Jorge E Cortes, Pei Lin, et al.
American Journal of Hematology|August 18, 2016
Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinibJorge E Cortes, Hanna J Khoury, Hagop M Kantarjian, et al.
Leukemia Research|June 15, 2007
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasiaFrancis J Giles, Alan F List, Michael Carroll, et al.
Blood|October 24, 2002
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responsesHagop M Kantarjian, Jorge E Cortes, Susan O'Brien, et al.
Leukemia & Lymphoma|June 23, 2025
Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITYMichael J Mauro, Rüdiger Hehlmann, Loretta A Williams, et al.
Leukemia|February 5, 2014
Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategyC D DiNardo, N Daver, N Jain, et al.
Patient Education and Counseling|March 22, 2021
Utility of a virtual counselor (VICKY) to collect family health histories among vulnerable patient populations: A randomized controlled trialCatharine Wang, Michael K Paasche-Orlow, Deborah J Bowen, et al.
British Journal of Haematology|October 3, 2002
Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survivalFrancis J Giles, Hagop M Kantarjian, B Nebiyou Bekele, et al.
Blood|June 8, 2018
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in <i>FLT3</i>-ITD-mutated, relapsed or refractory AMLJorge E Cortes, Martin S Tallman, Gary J Schiller, et al.
Pageof 59